{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:03:29Z","timestamp":1766138609397,"version":"build-2065373602"},"reference-count":51,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide a practical review of immune\u2010related adverse events (irAEs) that may be encountered in uro\u2010oncology patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a literature review of studies reporting irAEs including articles published through September 2023 for uro\u2010oncology patients and the potential relevancy for the practicing urologist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Immunotherapy has revolutionised cancer treatment, extending its impact to urological malignancies including for patients with urothelial, kidney, and prostate cancers. Immuno\u2010oncology (IO) compounds have achieved measurable and durable responses in these cancers. Urologists, choosing to administer or co\u2010manage IO patient care, should be prepared to understand, evaluate, and treat irAEs. This review discusses the spectrum of irAEs that can be encountered. Ongoing trials are exploring the use of immunotherapy at earlier stages of uro\u2010oncological diseases, thus underscoring the evolving landscape of urological cancer treatment. Paradoxically, some data suggests that the occurrence of irAEs is associated with improved oncological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immune\u2010related AEs, while manageable, may be life\u2010threatening and require lifelong therapy. A thorough understanding of AEs and toxicity of a novel drug class is imperative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16310","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:01:30Z","timestamp":1709578890000},"page":"524-531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Complications of\n                    <scp>immuno\u2010oncology<\/scp>\n                    care: what urologist should know"],"prefix":"10.1111","volume":"133","author":[{"given":"Valentina","family":"Grajales","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-7154","authenticated-orcid":false,"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"Carolina Urologic Research Center  Myrtle Beach SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt.15.17"},{"key":"e_1_2_8_3_1","unstructured":"U.S. Food & Drug Administration.Drugs@FDA: FDA\u2010approved drugs.2023. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed October 2023"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955894"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102360"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy232"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS504"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.028"},{"key":"e_1_2_8_13_1","first-page":"S763","article-title":"The immune\u2010related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials","volume":"83","author":"Robesti D","year":"2023","journal-title":"BJU Int"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00318"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-00241-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2212"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0889"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000293"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0555"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.016"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8583"},{"key":"e_1_2_8_33_1","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune\u2010related toxicities","volume":"4","author":"Villadolid J","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-7361"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-017-0540-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000412"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002220"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02355-9"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56026-5"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1641"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21176"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000586"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0137"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-41008-7_15"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2289"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.01.024"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0348-1"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666201230151224"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0055"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:29:50Z","timestamp":1761744590000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/bju.16310"],"URL":"https:\/\/doi.org\/10.1111\/bju.16310","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"2024-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}